Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients

TERT promoter (TERTp) mutations are important factors in papillary thyroid carcinomas (PTCs). They are associated with tumor aggressiveness, recurrence, and disease-specific mortality and their use in risk stratification of PTC patients has been proposed. In this study we investigated the prevalence...

Full description

Bibliographic Details
Main Authors: Dagmara Rusinek, Aleksandra Pfeifer, Jolanta Krajewska, Malgorzata Oczko-Wojciechowska, Daria Handkiewicz-Junak, Agnieszka Pawlaczek, Jadwiga Zebracka-Gala, Malgorzata Kowalska, Renata Cyplinska, Ewa Zembala-Nozynska, Mykola Chekan, Ewa Chmielik, Aleksandra Kropinska, Roman Lamch, Beata Jurecka-Lubieniecka, Barbara Jarzab, Agnieszka Czarniecka
Format: Article
Language:English
Published: MDPI AG 2018-09-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/19/9/2647
id doaj-4b1c0cb749b34151addb185acc3960e1
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Dagmara Rusinek
Aleksandra Pfeifer
Jolanta Krajewska
Malgorzata Oczko-Wojciechowska
Daria Handkiewicz-Junak
Agnieszka Pawlaczek
Jadwiga Zebracka-Gala
Malgorzata Kowalska
Renata Cyplinska
Ewa Zembala-Nozynska
Mykola Chekan
Ewa Chmielik
Aleksandra Kropinska
Roman Lamch
Beata Jurecka-Lubieniecka
Barbara Jarzab
Agnieszka Czarniecka
spellingShingle Dagmara Rusinek
Aleksandra Pfeifer
Jolanta Krajewska
Malgorzata Oczko-Wojciechowska
Daria Handkiewicz-Junak
Agnieszka Pawlaczek
Jadwiga Zebracka-Gala
Malgorzata Kowalska
Renata Cyplinska
Ewa Zembala-Nozynska
Mykola Chekan
Ewa Chmielik
Aleksandra Kropinska
Roman Lamch
Beata Jurecka-Lubieniecka
Barbara Jarzab
Agnieszka Czarniecka
Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
International Journal of Molecular Sciences
TERTp mutation
BRAF V600E
papillary thyroid cancer
author_facet Dagmara Rusinek
Aleksandra Pfeifer
Jolanta Krajewska
Malgorzata Oczko-Wojciechowska
Daria Handkiewicz-Junak
Agnieszka Pawlaczek
Jadwiga Zebracka-Gala
Malgorzata Kowalska
Renata Cyplinska
Ewa Zembala-Nozynska
Mykola Chekan
Ewa Chmielik
Aleksandra Kropinska
Roman Lamch
Beata Jurecka-Lubieniecka
Barbara Jarzab
Agnieszka Czarniecka
author_sort Dagmara Rusinek
title Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
title_short Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
title_full Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
title_fullStr Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
title_full_unstemmed Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish Patients
title_sort coexistence of tert promoter mutations and the braf v600e alteration and its impact on histopathological features of papillary thyroid carcinoma in a selected series of polish patients
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2018-09-01
description TERT promoter (TERTp) mutations are important factors in papillary thyroid carcinomas (PTCs). They are associated with tumor aggressiveness, recurrence, and disease-specific mortality and their use in risk stratification of PTC patients has been proposed. In this study we investigated the prevalence of TERTp mutations in a cohort of Polish patients with PTCs and the association of these mutations with histopathological factors, particularly in coexistence with the BRAF V600E mutation. A total of 189 consecutive PTC specimens with known BRAF mutational status were evaluated. TERTp mutations were detected in 8.5% of cases (16/189) with the C228T mutation being the most frequent. In six of the PTC specimens (3.2%), four additional TERTp alterations were found, which included one known polymorphism (rs2735943) and three previously unreported alterations. The association analysis revealed that the TERTp hotspot mutations were highly correlated with the presence of the BRAF V600E mutation and their coexistence was significantly associated with gender, advanced patient age, advanced disease stage, presence of lymph node metastases, larger tumor size, and tumor-capsule infiltration. While correlations were identified, the possibility of TERTp mutations being key molecular modulators responsible for PTC aggressiveness requires further studies.
topic TERTp mutation
BRAF V600E
papillary thyroid cancer
url http://www.mdpi.com/1422-0067/19/9/2647
work_keys_str_mv AT dagmararusinek coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT aleksandrapfeifer coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT jolantakrajewska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT malgorzataoczkowojciechowska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT dariahandkiewiczjunak coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT agnieszkapawlaczek coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT jadwigazebrackagala coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT malgorzatakowalska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT renatacyplinska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT ewazembalanozynska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT mykolachekan coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT ewachmielik coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT aleksandrakropinska coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT romanlamch coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT beatajureckalubieniecka coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT barbarajarzab coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
AT agnieszkaczarniecka coexistenceoftertpromotermutationsandthebrafv600ealterationanditsimpactonhistopathologicalfeaturesofpapillarythyroidcarcinomainaselectedseriesofpolishpatients
_version_ 1725285082094108672
spelling doaj-4b1c0cb749b34151addb185acc3960e12020-11-25T00:41:53ZengMDPI AGInternational Journal of Molecular Sciences1422-00672018-09-01199264710.3390/ijms19092647ijms19092647Coexistence of TERT Promoter Mutations and the BRAF V600E Alteration and Its Impact on Histopathological Features of Papillary Thyroid Carcinoma in a Selected Series of Polish PatientsDagmara Rusinek0Aleksandra Pfeifer1Jolanta Krajewska2Malgorzata Oczko-Wojciechowska3Daria Handkiewicz-Junak4Agnieszka Pawlaczek5Jadwiga Zebracka-Gala6Malgorzata Kowalska7Renata Cyplinska8Ewa Zembala-Nozynska9Mykola Chekan10Ewa Chmielik11Aleksandra Kropinska12Roman Lamch13Beata Jurecka-Lubieniecka14Barbara Jarzab15Agnieszka Czarniecka16Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTumor Pathology Department, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTumor Pathology Department, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTumor Pathology Department, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTumor Pathology Department, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandDepartment of Oncological and Reconstructive Surgery, Maria Sklodowska-Curie Institute, Oncology Center, Gliwice Branch, Wybrzeze Armii Krajowej 15, 44-101 Gliwice, PolandTERT promoter (TERTp) mutations are important factors in papillary thyroid carcinomas (PTCs). They are associated with tumor aggressiveness, recurrence, and disease-specific mortality and their use in risk stratification of PTC patients has been proposed. In this study we investigated the prevalence of TERTp mutations in a cohort of Polish patients with PTCs and the association of these mutations with histopathological factors, particularly in coexistence with the BRAF V600E mutation. A total of 189 consecutive PTC specimens with known BRAF mutational status were evaluated. TERTp mutations were detected in 8.5% of cases (16/189) with the C228T mutation being the most frequent. In six of the PTC specimens (3.2%), four additional TERTp alterations were found, which included one known polymorphism (rs2735943) and three previously unreported alterations. The association analysis revealed that the TERTp hotspot mutations were highly correlated with the presence of the BRAF V600E mutation and their coexistence was significantly associated with gender, advanced patient age, advanced disease stage, presence of lymph node metastases, larger tumor size, and tumor-capsule infiltration. While correlations were identified, the possibility of TERTp mutations being key molecular modulators responsible for PTC aggressiveness requires further studies.http://www.mdpi.com/1422-0067/19/9/2647TERTp mutationBRAF V600Epapillary thyroid cancer